WO2025162209 - PYRIDOPYRIDONE MAT2A INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND MEDICAL USE
National phase entry is expected:
Publication Number
WO/2025/162209
Publication Date
07.08.2025
International Application No.
PCT/CN2025/074523
International Filing Date
24.01.2025
Title **
[English]
PYRIDOPYRIDONE MAT2A INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND MEDICAL USE
[French]
INHIBITEUR DE PYRIDOPYRIDONE MAT2A ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT, ET UTILISATION MÉDICALE
[Chinese]
一种吡啶并吡啶酮类MAT2A抑制剂及其药物组合物、医药用途
Applicants **
ALICORN PHARMACEUTICAL CO., LTD
Inventors
LU, Pingbo
YANG, Jiale
WANG, Zhi
ZHU, Hui
TAN, Feiyu
LIU, Feng
Priority Data
202410146487.8
01.02.2024
CN
202410591800.9
13.05.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1961 | |
| EPO | Filing, Examination, Granting | 13417 | |
| Japan | Filing, Examination, Granting | 2246 | |
| South Korea | Filing, Examination, Granting | 2369 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
25,333
Contact Us
Abstract[English]
The present invention provides a compound as represented by formula I and an isomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and a pharmaceutical use as a MAT2A inhibitor. The present invention provides a MAT2A inhibitor compound which has a novel structure, high activity, good selectivity, and good oral absorption in rats. The compound has a good prospect of application in the prevention and/or treatment of indications related to MAT2A inhibition, such as cancer and autoimmune diseases.[French]
La présente invention concerne un composé représenté par la formule I et un isomère ou un sel pharmaceutiquement acceptable de celui-ci, une composition pharmaceutique le comprenant, et une utilisation pharmaceutique en tant qu'inhibiteur de MAT2A. La présente invention concerne un composé inhibiteur de MAT2A qui présente une nouvelle structure, une activité élevée, une bonne sélectivité et une bonne absorption orale chez le rat. Le composé présenteune bonne perspective d'application dans la prévention et/ou le traitement d'indications liées à l'inhibition de MAT2A, telles que le cancer et des maladies auto-immunes.[Chinese]
本发明提供了一种如式I所示的化合物及其异构体、或其药学可接受的盐，其药物组合物和作为MAT2A抑制剂的药物用途。本发明提供了一类结构新颖、活性强、选择性好、大鼠体内口服吸收良好的MAT2A抑制剂化合物，该类化合物在预防和/或治疗MAT2A抑制有关的适应症比如癌症、自身免疫性疾病等具有良好的应用前景。